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Many attempts have been made or are ongoing for HIV prevention and HIV cure. Many
successes are in the list, particularly for HIV drugs, recently proposed also for prevention.
However, no eradication of infection has been achieved so far with any drug. Further, a
residual immune dysregulation associated to chronic immune activation and incomplete
restoration of B andT cell subsets, together with HIV DNA persistence in reservoirs, are still
unmet needs of the highly active antiretroviral therapy, causing novel “non-AIDS related”
diseases that account for a higher risk of death even in virologically suppressed patients.
These “ART unmet needs” represent a problem, which is expected to increase by ART
roll out. Further, in countries such as South Africa, where six millions of individuals are
infected, ART appears unable to contain the epidemics. Regretfully, all the attempts at
developing a preventative vaccine have been largely disappointing. However, recent thera-
peutic immunization strategies have opened new avenues for HIV treatment, which might
be exploitable also for preventative vaccine approaches. For example, immunization strate-
gies aimed at targeting key viral products responsible of virus transmission, activation,
and maintenance of virus reservoirs may intensify drug efficacy and lead to a functional
cure providing new perspectives also for prevention and future virus eradication strate-
gies. However, this approach imposes new challenges to the scientific community, vaccine
developers, and regulatory bodies, such as the identification of novel immunological and
virological biomarkers to assess efficacy end-points, taking advantage from the natural his-
tory of infection and exploiting lessons from former trials. This review will focus first on
recent advancement of therapeutic strategies, then on the progresses made in preventa-
tive approaches, discussing concepts, and problems for the way ahead for the development
of vaccines for HIV treatment and prevention.
Keywords: HIV-1 vaccine, therapeutics, HAART, functional cure, clinical studies, preclinical and clinical
proof-of-concept studies
INTRODUCTION
The HIV epidemic represents one of the major health challenges
worldwide, with important social and economical implications for
public health. Approximately 34 million people are currently liv-
ing with HIV, with a total of 24 million accumulated AIDS-related
deaths, and 2.6 million new infections (1). With an estimated 6.1
million people living with HIV, South Africa’s epidemic remains
the largest in the world. Worldwide, the pace of ART roll out
to provide universal coverage is outpaced, especially in develop-
ing countries, by the number of new infections, rendering the
objective almost impossible to achieve (2). Moreover, since ART
alone cannot eliminate HIV-1 infection, the therapeutic regi-
men must be maintained for the lifetime, and this represents a
major challenge for the patient (need of strict adherence, poor
drug tolerability, drug interactions among antiretroviral agents,
and other medications), which may lead to virologic failure and
development of drug resistance, and an unbearable economical
burden for the National Health Systems. Further, implementa-
tion of HAART therapeutic regimens requires a close clinical and
laboratory monitoring and the commitment of large human and
financial resources with an increasing economic burden for both
developing as well as developed countries. This imposes major
logistic obstacles to most developing countries, including an insuf-
ficient HIV testing, particularly in rural areas, the lack of infra-
structures and socio-economical barriers (3–5). Finally,ART alone
is unable to eliminate HIV-1 infection. In fact, there is evidence of
persistent viral replication in compartments and reservoirs insen-
sitive even to HAART (6). The discrete, though persistent, viral
replication as well as HAART-resistant cell-to-cell virus transmis-
sion and homeostatic proliferation of infected memory T cells
maintain the replenishment of HIV-1 reservoirs (7–16) ensuring
virus persistence, while sustaining a residual immune dysregula-
tion, which is associated to chronic immune activation, incomplete
restoration of CD4 T cell counts, and lack of replenishment of cen-
tral memory CD4 and CD8 T cells, which collectively represent
the unmet therapeutic needs of ART. In turn, these unmet needs
contribute to the residual disease and clinical complications. As
a result, HIV-1 infection in the HAART era remains a chronic
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progressive disease and is now associated with novel syndromes,
termed non-AIDS-associated diseases, including atherosclerosis,
cardiovascular diseases, kidney and liver diseases, tumors, early
aging, and drug-resistant co-infections (17, 18). These are life-
threatening diseases reducing the quality of life of patients still
experiencing a high-risk of hospitalization and death. The unmet
needs of HAART have a heavy social impact and represent a
considerable economic burden for National Health Systems.
Thus, novel, most effective therapeutic strategies are essen-
tial to allow a containment of the human, social, and financial
resources necessary for the delivery of an effective health care
against HIV/AIDS. Indeed, new approaches capable of targeting
key pathogenic mechanisms of the virus life cycle, including the
establishment and maintenance of virus reservoirs, are urgently
needed to circumvent these problems and more effectively attack
the virus, either as cART intensification or as an alternative to
cART. To this end, novel drugs targeting additional steps in the
virus life cycle, gene therapy approaches to render host cells resis-
tant to infection, purging (“shock and kill”) strategies to empty
viral reservoirs, as well as several different therapeutic immu-
nization approaches are presently being investigated [reviewed in
Ref. (19)].
THERAPEUTIC IMMUNIZATION STRATEGIES
In recent years, a growing attention has been given to the devel-
opment of therapeutic HIV vaccines for treating people already
infected with HIV-1. The development of an effective therapeutic
vaccine might help at either intensifying ART efficacy, thus fulfill-
ing the ART unmet needs, or, hopefully, at substituting the anti-
retroviral treatment (Table 1). The achievement of either objective
might represent a considerable progress beyond the“state of art”of
current therapeutic strategies against HIV infection, while ensur-
ing a most favorable cost/efficacy ratio. In addition, an effective
therapeutic vaccine may offer a promising alternative strategy to
the recurrent failure of preventive HIV vaccines, based on the con-
sideration that it can reduce HIV replication and transmission to
healthy individuals. Moreover, therapeutic vaccination may apply
Table 1 | Rationale for therapeutic immunization of HIV-infected
individuals.
In HIV-infected Drug-Naïve individuals
Delay or block of progression to AIDS or ARV Therapy
In HIV-infected individuals in need of therapy or ARV-treated
1. cART intensification to:
a) Accelerate time-to-response to therapy
b) Block or reduce virus transmission
c) Help reduce reservoir size in patients given intensive ARV in acute
infection
d) Solve unmet needs of ART (immune activation, immune defects,
and proviral DNA)
2. Drug simplification
3. Therapy interruption after ARV intensification
to different intervention strategies according to its efficacy, ranging
from cART intensification to drug simplification or, for the most
effective ones, therapy interruption, or no cART initiation (see
Tables 1 and 2). Thus, therapeutic vaccination has several advan-
tages on the preventative counterpart, including a rapid and cost–
effective proof-of-concept assessment of efficacy even in small
phase I/II trials, the possibility to rapidly identify relevant bio-
markers of protection, and it may be worth to develop even if not
fully effective, since it may be used in association with antiretro-
viral drugs (see Tables 1 and 2). In fact, HIV therapeutic vaccines
have been the topics of a conference recently held in Bethesda,
MD, USA (20) underscoring the renewed and growing interest
to pursue these types of immune interventions, whose potential
and feasibility is becoming increasingly appreciated. However, a
potential limitation of therapeutic vaccination as compared to the
preventative one is that HIV-1 infected individuals may have a
reduced immunocompetence, which may hamper both the elici-
tation and the strength of protective immune responses induced
by the vaccine. As immune competence in HIV-1 infected individ-
uals progressively declines over time, therapeutic vaccination early
in the course on infection may be required to ensure best efficacy.
As discussed later, this might also limit reservoir establishment and
promote virus eradication.
Although no therapeutic vaccine has been market approved,
a growing number of vaccine candidates are being evaluated in
phase I/II clinical trials conducted in both naïve and/or ART-
treated patients [reviewed in Ref. (21) a comprehensive list of
vaccine candidates available at: http://www.pipelinereport.org/
sites/g/files/g575521/f/201407/Cure%20Immune%20Based%20
and%20Gene%20Therapies.pdf]. Here, we briefly review the most
representative of the diverse approaches undertaken.
InnaVirVax – (a spin-off of INSERM, Evry, France) is develop-
ing VAC-3S, a vaccine constructed to induce a humoral immune
response against a highly conserved region of the envelope pro-
tein gp41 of HIV-1 known as 3S. The 3S domain has been shown
to induce the expression of NKp44L on uninfected CD4 T cells,
rendering them susceptible to lysis by NKp44+ activated NK cells,
thus contributing to the massive T cell loss, which far exceeds the
number of HIV-infected lymphocytes (22). Upon promising data
in monkeys (23), it has recently been announced the start of a
randomized, double-blind, placebo-controlled phase II study in
90 cART-suppressed adult subjects, with the primary endpoint
being the induction of anti-3S antibodies, while overall tolerance
and clinical safety, together with a comprehensive evaluation of
the immunological end-points, inflammatory biomarkers, and
vaccine’s immunogenic characteristics, represent the secondary
end-points (ClinicalTrials.gov Identifier:NCT02041247).
Bionor Pharma (Oslo, Norway) is developing Vacc-4x, a
peptide-based vaccine consisting of four synthetic peptides based
on the HIV-1 p24 protein, injected multiple times intradermally
together with GM-CSF. The results from a double-blind, random-
ized, phase II study conducted in 135 patients on effective cART
showed that Vacc-4x is sae, immunogenic, and contributes to viral
load reduction after cART interruption. However, the proportion
of participants resuming cART before the end of the study and
the CD4 T cell counts recorded during the treatment interrup-
tion showed no benefit of vaccination. In addition, it requires a
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Table 2 | HIV/AIDS preventative and therapeutic vaccine . . . the continuum.


















HIV test CD4 counts CD4 counts CD4 counts
Viral load Viral load Viral load Viral load
CD4 counts Time to cART initiation Time to infection control
Secondary (long-term)
end-points
None Proviral DNA (Integrated, non-integrated, total)
Neutralization of Tat/Env entry in DCs
Markers of immune activation and reconstitution
long and complex vaccination schedule while providing a limited
impact on viral load (24).
SEEK (London, UK) is developing PepTcell, a T cell epitope
HIV vaccine consisting of synthetic peptides derived from the con-
served regions of Vpr, Vif, Rev, and Nef. A randomized, placebo-
controlled, dose finding Phase Ib/II trial was recently completed
in 55 HIV-positive volunteers. After just a single subcutaneous
injection, a significant reduction in viral load was observed in a
minority of vaccinees who had received the high dose and had
mounted both B and T cell responses to the vaccine (25).
FIT Biotech (Tampere, Finland) is developing GTU® MultiHIV
multi-gene, a vaccine based on six viral HIV proteins. The vaccine
(clade B) has been tested in 60 untreated, asymptomatic, HIV-1
subtype C infected adults enrolled in a single-blinded, placebo-
controlled Phase II trial in South Africa. The vaccine was safe
and well tolerated. Significant declines in plasma HIV-RNA load
and increases in CD4+ T cell counts were observed in the vaccine
group compared to placebo, which were more pronounced after
intramuscular (IM) administration (26).
Similarly, Profectus Biosciences (Baltimore, MD, USA) is devel-
oping TheraVax, a multi-antigen HIV vaccine in which a plasmid
DNA encoding Env, Gag, Pol, Nef, Tat, and Vif is administered
by electroporation, in combination with interleukin-12 plasmid
DNA followed by a boost with same the antigens vectored by a
recombinant vesicular stomatitis virus (rVSV) delivered intramus-
cularly. A randomized, double-blind, placebo-controlled phase
I study in cART-treated patients (n= 50) has started in USA
and results are expected by November 2016 (ClinicalTrials.gov
Identifier: NCT01859325).
Genetic Immunity (Budapest, Hungary) is developing Der-
maVir, a DNA vaccine encoding 15 HIV proteins administrated
by skin patches. A randomized, placebo-controlled, dose-ranging
Phase II study in 36 HIV-infected individuals naïve to cART con-
firmed that the vaccine, administered three times, 6 weeks apart,
is safe and immunogenic (27). A 0.5 Log10 reduction of plasma
RNA copies per milliliter was seen in the arm immunized with the
intermediate DermaVir dose (0.4 mg). However, no amelioration
of CD4+ T cell counts was recorded (27).
GeoVax (Atlanta, GA, USA) is developing MVA/HIV62B, a two
components’ vaccine: a recombinant DNA vaccine and a recombi-
nant MVA (modified vaccinia Ankara) vaccine. Both produce non-
infectious virus-like particles displaying HIV clade B Env, Gag, and
Pol proteins. An open label phase I study in HIV-1 infected adults
on successful ART who initiated therapy within 18 months from
seroconversion (n= 9) is ongoing (ClinicalTrials.gov Identifier:
NCT01378156).
Theravectys SAS (a spin-off of the Pasteur Institute, Paris,
France) is developing THV01, a vaccine based on lentiviral vectors
(01 and 02), both encoding HIV-1 Clade B Gag, Pol, and Nef pro-
teins and exploiting the HIV DNA flap sequence, which permits
the nuclear import of HIV in non-dividing cells, including den-
dritic cells (DCs), thus optimizing antigen immunogenicity. Upon
promising efficacy data in macaques (28), Theravectys recently
announced the initiation of a Phase I/II randomized, double-blind,
placebo-controlled trial of 36 patients in 6 clinical centers aimed at
assessing the safety and tolerance of the vaccine and measure the
quality and intensity of the induced immune response, which, in
perspective, should allow therapy interruption (ClinicalTrials.gov
Identifier: NCT02054286).
Argos Therapeutics (Durham, NC, USA) is developing tailor-
made vaccines in that autologous DCs, loaded ex vivo with RNA
encoding four (Gag, Nef, Rev, and Vpr) of the patient’s own HIV
antigens plus CD40L, are reinjected into the patient intradermally,
four times, 4 weeks apart. Results from the Phase IIa (n= 24) study
indicate delay of cART resumption in treated subjects, but no
improvement of CD4+ T cell counts (29).
Of note, none of these vaccine candidates is aimed at intensi-
fying HAART efficacy in order to attack the virus reservoirs and
restore the immune homeostasis. To this aim, the Italian National
AIDS Center is developing a vaccine based on the biologically
active HIV Tat protein. Results from phase I preventative (ISS P-
001, ClinicalTrials.gov identifier: NCT00529698) and therapeutic
(ISS T-001, ClinicalTrials.gov identifier: NCT00505401) studies
have indicated that the Tat vaccine is safe and immunogenic (30–
32) and more recently results from a randomized phase II trial (ISS
T-002) in virologically suppressed HAART-treated subjects (Clin-
icalTrials.gov NCT00751595) indicate that Tat vaccination exerts
a positive impact on immune activation and T and B cell dysregu-
lation [Ref. (33, 34) and Ensoli et al., manuscript submitted], con-
firming the role of Tat in the pathogenesis of the HAART unmet
needs. Tat immunization induced a restoration of CD4+ and
CD8+ T cell number and functional central memory T cell subsets,
of B and NK cell number and a reduction of immune activation as
compared to subjects under effective HAART (33). Of importance,
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Tat immunization induced a statistically significant reduction of
blood HIV-1 DNA load [Ref. (34) and Ensoli et al., manuscript
submitted]. Effects were greatest with Tat 30µg, given three times
at monthly intervals, and under Protease Inhibitors (PI)-based reg-
imens, with a predicted 70% HIV-1 DNA decay after 3 years from
vaccination and a half-life of 88 weeks. HIV-1 DNA decay was asso-
ciated with anti-Tat Abs and neutralization of Tat-mediated entry
of oligomeric Env in DCs, which predicted HIV-1 DNA decay. A
phase II randomized, placebo-controlled clinical trial (ISS T-003,
ClinicalTrials.gov Identifier: NCT01513135) of the Tat vaccine has
just been completed in South Africa in 200 HAART-treated indi-
viduals and the results are expected by the end of 2014. Strategies
are in development for phase III registrative trials.
More recently, also Biosantech SA – France (a spin-off of ANRS)
started developing a vaccine based on a synthetic form of Tat
derived from Tat Oyi, an attenuated clade B HIV field isolate.
Based on results in monkeys (35), Biosantech recently announced
the start of a therapeutic phase I study in 48 patients under cART.
The strategy is aimed to therapy interruption.
As an alternative to therapeutic vaccines strategy, Sangamo Bio-
Sciences (Richmond, CA, USA), is developing SB-728-T, an ex vivo
gene therapy approach by which CD4+ T cells drawn from HIV-
infected patients are modified ex vivo to disrupt the CCR5 gene in
autologous CD4+ T cells, expanded, and reinfused to the patient.
Results from a phase I study indicate that both CCR5 alleles have
to be disabled to make the treatment effective (36). However, the
complexity and costs of this approach, together with serious safety
issues represent a major disadvantage, rendering the immune ther-
apy, even if it was effective, accessible only to a small fraction of the
HIV population (37). Nevertheless, alternative strategies to render
the patient’s cells resistant to infection are being developed and
may turn out to be more feasible than at present (38–40).
Altogether, the above studies demonstrate that the HIV/AIDS
therapeutic vaccine field is rapidly expanding and portraits a
substantial variety of approaches, which differ sensibly in many
aspects, the most relevant being the antigen chosen (unlike pre-
ventative vaccines, regulatory and accessory genes are frequently
targeted; in some cases almost the entire HIV genome is targeted),
and the delivery systems, which range from simple subcutaneous,
intradermal, or intramuscular vaccine administration to reinfu-
sion of autologous DCs loaded ex vivo with the selected anti-
gen(s), or, for the gene therapy approaches, of genetically modified
autologous target cells.
As compared to preventative approaches, the therapeutic set-
ting provides the unique opportunity to evaluate vaccine efficacy
in a more rapid and convenient manner, hopefully speeding up
the identification and development of effective vaccine candidates.
However, key clinical end-points and appropriate virological and
immunological biomarkers to properly assess the therapeutic effi-
cacy in more advanced trials still need to be established and agreed
upon. To address these issues is a priority to grant advancement
of therapeutic, and possibly preventative, vaccines.
PREVENTATIVE VACCINATION STRATEGIES
Despite almost 30 years of efforts, a preventative HIV vaccine is
still lacking and only four types of HIV vaccines have been tested
in six HIV vaccine efficacy trials so far (41, 42).
The first efficacy trials were conducted in high-risk populations
immunized with a mixture of monomeric form of gp120 Env from
two different clade B (VAX004) or from clade B and E (VAX003).
Both vaccines, aimed at inducing neutralizing Abs (NAbs), failed to
prevent infection (43, 44) and investigators turned their attention
and hopes to vaccines aimed at inducing CD8 T cell responses.
The MRK rAd5 vaccine consisted of HIV-1 Gag, Pol, and Nef
delivered by three different recombinant adenovirus 5 (rAd5) vec-
tors and aimed at inducing protective CD8+ T cell responses. The
phase IIb “test-of-concept” STEP trial (also termed HVTN 502 or
Merck V520-023 study) was stopped due to evidence of enhanced
risk of acquisition of infection, especially in those uncircumcised
and with pre-existing antibodies to the vector. Because of this seri-
ous safety concern, the companion Phambili trial (HVTN 503)
conducted in South Africa was also halted (45, 46). A very recent
analysis confirmed that also in the Phambili trial the rate of acqui-
sition of HIV infection was higher among vaccinees, especially
during the long-term follow-up, for unknown reasons, although
early unblinding due to trial stop might have influenced risk
behavior (47). Of note, the temporal windows of increased risk
of acquisition were the opposite in HVTN 502 (early after vac-
cination) and HVTN 503 (late after vaccination), underscoring
the complexity of the factors involved, including differences in
the risk populations targeted. A detailed analysis of these rAd5-
based trials showed a strong activation of Ad5-specific (but not
HIV-specific) CD4 T cells in the gut mucosa of vaccinees, which
may explain their enhanced susceptibility to infection (48), a find-
ing reproduced in the monkey model (49). Nevertheless, post hoc
“sieve” analysis of breakthrough infections demonstrated that the
vaccine had exerted some immune pressure, as indicated by the
appearance of virus-escape mutants (50). However, the immune
pressure was against HIV-1 epitopes contained predominantly in
highly variable regions infrequently targeted in the course of the
natural infection, domains which can presumably tolerate escape
mutations (51). Thus, vaccines aimed at generating CD8+ T cell
responses may still be a valid option, provided that better strategies
and vectors are identified.
In fact, another rAd5-based preventative phase III trial was
stopped in 2013 due to evident lack of efficacy (52). The HVTN
505 vaccine consisted of HIV-1 Gag, Pol, Nef, and three differ-
ent Env from clade A, B, and C, delivered as DNA for priming
followed by boosting with rAd5 vectors coding for all but Nef anti-
gen. Despite these rAd5 vectors were less immunogenic than those
used in the STEP trial and despite individuals seropositive for rAd5
were excluded from the trial, breakthrough infections were slightly
higher among vaccinees as compared to placebo, casting serious
doubts on whether to proceed further with adenoviral vectors
(53) and, more in general, with vectors whose immune activating
properties may exceed the capability to induce protective immune
responses, thus favoring, rather than blocking, susceptibility to
infection (48).
So far, only one efficacy trial has provided some evidence of
low and transient (60% at 12 months but 31% at 42 months)
protection from acquisition of infection. The RV144 Thai trial
was an Env-based vaccine consisting of a priming with the
CD4+ T cell-stimulating ALVAC canarypox expressing HIV-1
gag/pr/gp41/gp120 followed by the VAX004 gp120 Env of B and
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E clade, the very same used in the AIDSVAX trial reported above.
Intriguingly, protection correlated with titers of IgG against the
V1V2 loop of Env, which were not neutralizing but mediating
ADCC, whereas, when present, high titers of IgA against the C1
domain of Env actually abolished the IgG effect by interfering with
the IgG binding to V1V2 (54). Of note, mostly low to medium-
risk individuals were enrolled in the RV144 Thai trial, and vaccine
efficacy dropped to 3.7% when only high-risk individuals were
considered (55). Nevertheless, this was considered an important
step ahead in vaccine development and stemming from these
results, several new trials have been designed to reproduce and
possibly increase the efficacy (56).
It is worth considering that the Env-protein based vaccines
tested so far in clinical trials have utilized gp120 Env monomers
or a truncated form of gp160 (HVTN 505), although the spikes
present on the infectious virion are constituted by trimers of
gp160, which differ from monomeric gp120 Env in terms of anti-
genic properties and conformational epitopes displayed (57). This
further emphasizes the concept that vaccine design should be more
“pathogenesis-driven” in order to effectively target key virus mole-
cules, a notion to carefully consider in future vaccine development.
An oligomeric Env that closely resembles the native protein has
been recently generated, which may represent a better immunogen
and a useful tool to detect valuable anti-Env Abs (58).
On the other hand, approaches based on vaccines aimed at
inducing protective CD8+ T cell responses only (HVTN 502 and
503) or in association to anti-Env antibodies (HVTN 505) have
been largely disappointing. However, recent data obtained in the
macaque model provided some encouraging results, although not
necessarily easily transferable to human. This type of vaccine it is
not expected to protect from infection acquisition, but rather to
contain infection (i.e., low to undetectable plasma viral load and
no CD4+ T cell loss), preventing progression to disease as well as
virus transmission (Figure 1).
Strong control and apparent clearance of infection upon
mucosal challenge with the pathogenic SIVmac239 was obtained
with a replication competent simian cytomegalovirus (CMV) vec-
tor engineered to express SIV Gag, Tat, Rev, Nef, Env, and Pol
(59–61). This strategy induced effector memory CD8 T cells which
localized in peripheral tissues, including the mucosal portal of
entry of the virus, thus providing the opportunity for the CTLs to
attack the virus prior to dissemination. In fact, protected macaques
experienced a reduced peak viremia, which rapidly subsided to
undetectable levels, no CD4 T cell loss, no seroconversion, poor
establishment of virus reservoirs in lymphoid tissues and effector
tissues, eventually disappearing, a finding consistent with eradica-
tion of the infection (59–61). Protection appeared to be mediated
by effector T cells present at the site of infection,although they were
able to protect only 50% of the vaccinated monkeys, with the other
half experiencing an infection comparable to controls (59–61).
Intriguingly, CD8 T cells the effectors were restricted prevalently
by class II rather than class I MHC antigens, and responses were
very broad and persistent, features that appear to be peculiar to
the replication competent modified CMV vector used (62). Besides
underscoring the importance of the vector in the response to a vac-
cine, which also poses safety issues that will have to be exhaustively
addressed before testing in human, this strategy provides a further
FIGURE 1 | Control of HIV-1 by vaccines that stimulate CTLs. Effect of
various T cell-stimulating vaccines (key) on viral load over time (with
infection on day 0) during natural infection with HIV or SIV, showing the
decrease in viral load achieved without a vaccine (none), by CTL responses
[partial control; as in Ref. (92), for example], by the RhCMV vaccine (slow
eradication) (60, 61) and by a hypothetical vaccine that targets the virus at
the site of infection (rapid eradication). Reproduced with permission from
Ref. (61).
indication that, to be effective, T cell responses have to be already
in place at the portal of entry when the virus attacks. Still, if this
defense line is overcome, the infection proceeds unaffected, indi-
cating that effector T cells are necessary but not always sufficient
to afford protection.
While the above strategy was aimed at inducing a specific type
of effector cell, others are focusing on the selection of relevant epi-
topes [reviewed in Ref. (63)]. Mosaic antigens (64) and conserved
antigens (65, 66) represent two potential strategies to address the
challenges of global HIV-1 diversity (Figure 2). The first takes
advantage of bioinformatics to generate mosaic antigen to cover
most of the variants of each epitope displayed by circulating viruses
with the aim of increasing the breadth of humoral and cellular
immune responses, whereas conserved antigens aim to focus cel-
lular immune responses on the most conserved viral sequences.
Although the mosaic antigen approach seems more promising and
has shown some efficacy in preclinical models (67), both strategies
needs major improvements (better targeting of relevant epitopes,
superior immunogenicity, durable immunity, and identification
of correlates of protection) prior to progress to clinical trials.
A further approach based on a “pathogenetic” assumption,
and thus aimed at inducing effective immune responses against
a key HIV virulence factor, has been developed by targeting
the HIV Tat protein. Tat vaccination represents an example of
a “pathogenic-driven” intervention potentially effective for both
preventative and therapeutic objectives, since it is aimed at block-
ing virus transmission/spreading. The rationale is based on the
evidence that HIV-1 Tat, which is necessary for HIV gene expres-
sion, replication, and cell-to-cell transmission, appears also to be
critical in the initial steps of virus acquisition. In fact, it has been
recently shown that Tat, which is present on virus particles, binds
to Env spikes promoting HIV infection of DCs and spreading
to T lymphocytes even in the presence of anti-Env NAbs and that
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anti-Tat Abs are necessary to restore neutralization (Figure 3) (68).
This evidence provides some explanation to the repeated failure
of preventative vaccines based solely on Env and indicates that
FIGURE 2 | Vaccines that deal with HIV-1 variability. Construction of
vaccines based on viral sequences in four viral isolates (top; simplified
representation): horizontal lines indicate viral sequences; circles indicate
sites of greatest variability between isolates (and potential escape
mutations from CTL pressure; there may be more than two alternative
sequences at each spot); and blue lines indicate regions of relative
conservation (although in reality no region of HIV-1 is invariant). The mosaic
vaccine (middle) is constructed to include the most common variants from
the isolates in as few strands as possible while conserving naturally
occurring sequence stretches. In the conserved region-containing vaccine
(bottom), the relatively conserved regions (blue) are excised and then are
“stitched” together (which creates an unnatural junctional region). The
regions typically vary from 30 to 120 amino acids in length. Reproduced
with permission from Ref. (63).
Tat may represent an optimal target for preventative interventions
either alone or in combination with oligomeric Env.
Preclinical studies in cynomolgus monkeys have shown that
immunization with a biologically active Tat protein or tat DNA
is safe, elicits a broad and specific immune response and, most
importantly, induces a long-term protection against infection with
a highly pathogenic SHIV-89.6P encoding Tat of HIV-1, which
rapidly causes AIDS and death in these monkeys (69, 70). Both
Tat protein and tat DNA elicited memory Tat-specific Abs, CD4+,
and CD8+ T cell responses in protected monkeys, which did not
show signs of systemic infection throughout a 104-week follow-up
or even upon a further boosting with tetanus toxoid (71), provid-
ing clear evidence of long-term containment of virus replication
and spread in blood and tissues (72). A retrospective analysis of
112 Mauritian cynomolgus macaques from different preclinical
trials, vaccinated (n= 67) or not (n= 45) with Tat and challenged
with the SHIV-89.6P, showed that vaccination induced a signif-
icant reduction of the rate of infection acquisition at 10 MID50
(P < 0.0001), and contained acute CD4+ T cell loss at 15 MID50
(P = 0.0099). Of importance, vaccination also contained CD4+ T
cell depletion (P = 0.0391) during chronic infection, irrespective
of the challenge dose (73).
In a different approach, rhesus macaques primed mucosally
with two replicating adenoviruses expressing HIV-1 Env and Tat,
respectively, and boosted with the Tat and Env proteins became
all infected following high dose intravenous SHIV-89.6P chal-
lenge. However, the Tat/Env vaccinated monkeys reduced chronic
FIGURE 3 | Outcome of DC infection in the absence or presence ofTat,
anti-Env, and/or anti-Tat antibodies. Tat redirects HIV to RGD-binding
integrins evading neutralization by anti-Env Abs and both anti-Env and anti-Tat
Abs are required to block infection. Extracellular Tat released by infected
neighbor cells binds to trimeric Env on HIV, decreasing recognition of C-type
lectin receptors and promoting engagement of RGD-binding integrins, which
are expressed by inflammatory DCs, macrophages, and endothelial cells
(ECs) present at the site of infection. As a result, virions escape neutralization
by anti-Env Abs directed against high mannose determinants and enters
target cells upon binding to RGD-binding integrins. Anti-Tat Abs neutralize this
binding, preventing virus entry through RGD-binding integrins. DC-SIGN:
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin;
SIGN-R: homolog of DC-SIGN present on ECs; MR: mannose receptor
[modified from Ref. (68)].
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viremia by four logs as compared to controls (P < 0.0001). Of note,
control of infection correlated with Tat and Env binding Abs (74).
Protection or containment of infection were also observed in
cynomolgus macaques co-immunized with HIV-1 Tat and Env
proteins and challenged intrarectally with a high dose (70 MID50)
of the R5-tropic SHIVSF162P4cy (68). In this case, the macaques
had been primed twice intranasally with HIV-1 Tat and Env, given
together with the LT-K63 mucosal adjuvant, and then boosted
subcutaneously with Tat plus Env in Alum. No infection or a sta-
tistically significant reduction of viral loads and proviral DNA
were observed in the vaccinated monkeys as compared to con-
trols. Notably, proviral load in the inguinal lymph nodes was
significantly lower in vaccinated monkeys as compared to controls,
whereas it did not differ significantly in rectal biopsies, strongly
suggesting the block of virus dissemination from the portal of
entry (68).
In a further approach, the sterilizing immunity or control of
infection observed in rhesus macaques immunized with a multi-
component vaccine (multimeric HIV-1 gp160, HIV-1 Tat, and SIV
Gag-Pol particles) delivered either systemically or mucosally and
challenged orally or intrarectally with the C clade r5-tropic SHIV-
1157ip correlated only with anti-Tat Abs against the N-terminus
of Tat, as determined by a novel biopanning strategy which, using
recombinant phages encoding random peptide libraries, allows a
complete and unbiased profiling of the antibody repertoire and
identification of epitopes associated with vaccine protection (75).
These studies strongly suggest that the induction of anti-Tat Abs
may be key to achieve protective immunity against HIV/AIDS. In
this regard is worth to note that in natural HIV infection, anti-Tat
Abs are produced by only a small fraction of individuals (76, 77),
while, in contrast, high Ab titers are produced against all other
viral products (78). The reason for such a limited anti-Tat Ab
response is unclear. However, when present, anti-Tat Abs correlate
with the asymptomatic state and lower or no disease progression
(79–83). In particular, a cross-sectional and longitudinal study,
on 252 HIV-1 seroconverters, with a median follow-up time of
7.2 years, indicated that the presence of anti-Tat Abs is predic-
tive of a slower progression to AIDS or immunodeficiency (83).
Progression was faster in persistently anti-Tat Ab-negative than
in transiently anti-Tat Ab-positive subjects, whereas no progres-
sion was observed in individuals persistently anti-Tat-Ab positive
(83). Thus, anti-Tat Abs may have a protective role and represent
a predictive biomarker of slower progression to AIDS.
The effects of anti-Tat Abs on the immunological, virologi-
cal, and clinical outcome of HIV-infected subjects were recently
assessed in a prospective observational study (ISS OBS T-003,Clin-
icalTrials.gov NCT01029548) conducted in asymptomatic drug-
naïve HIV-infected adult volunteers (84). A significant association
between the presence of anti-Tat Abs and a slower disease progres-
sion was found. In particular, anti-Tat Ab-positive patients showed
a remarkable preservation of CD4+ T cells and containment of
viral load for the entire follow-up (3 years), and no individuals
with high levels of anti-Tat Abs initiated HAART during follow-
up (84). Of note, the association of increasing anti-Env IgG titers
with a lower risk of starting HAART occurred only in the pres-
ence of anti-Tat Abs, suggesting that anti-Tat and anti-Env Abs
combined have increased HIV neutralizing effects by blocking the
Tat/Env complex formation and virus entry, as shown earlier both
in vitro and in vivo (68). Thus, both anti-Tat and anti-Env Abs
appear to be required to efficiently block HIV disease progres-
sion. In contrast, anti-Env or anti-Gag Ab titers had no significant
effects on CD4+ T cell counts and viral load in patients naïve to
therapy with or without anti-Tat Abs (84).
Of importance, the results of a phase I safety and immuno-
genicity clinical trial (ISS P-001, ClinicalTrials.gov identifier:
NCT00529698), indicate that Tat immunization is safe in HIV-
negative healthy individuals and highly immunogenic, as it
induced high titers of cross-clade, neutralizing anti-Tat Abs [(30–
32), and unpublished results]. More recently a phase I, open label
trial was conducted to assess the safety and immunogenicity in
HIV uninfected healthy adult volunteers of a preventative vac-
cine based on the association of recombinant HIV-1 biologically
active Tat and oligomeric Env deleted in the V2 region proteins
(ISS P-002, ClinicalTrials.gov identifier: NCT01441193), which is
currently under analysis.
DISCUSSION AND PERSPECTIVES
An innovative targeting for HIV vaccine development should
exploit lessons from former trials and pathogenetic mechanisms,
taking advantage of the natural history of infection in humans
(epidemiology, spontaneous control of infection). In fact, they
provide valuable information: either the vaccine did not induce
the responses desired and the immunization strategy has to be
improved or changed, or it did it, but the responses were not
protective, and the immunogen must be redesigned or the target
antigen changed.
So far, HIV vaccine design based on structural knowledge has
not been successful, nor have been empirical vaccines, reinforcing
the concept that a rational pathogenetic approach must be under-
taken to identify key virulence factors to be exploited for vaccine
targeting. A “pathogenesis-driven” approach should be aimed at
targeting key viral products responsible of virus transmission, acti-
vation and maintenance of virus reservoirs. Stemming from these
considerations one may then argue whether a preventative vaccine
should actually be different from a therapeutic one: a preventative
vaccine capable of blocking virus entry and transmission should
also be able to block virus spread within the infected host and,
vice versa, a therapeutic vaccine targeting key steps of the virus life
cycle and/or replication may rapidly control intra-host spread-
ing after acquisition and hopefully eradicate the infection. In both
cases, the rationale for vaccine design is to target key HIV virulence
factor(s) required for virus entry/transmission and/or spreading.
This is true in both healthy and already infected people, even those
on suppressive HAART. In fact, in considering these two extremes,
it appears that the viral dynamics is very similar. For infection
acquisition, the virus must find/induce optimal conditions for the
infection to occur, as indicated by the low transmission rate and
the existence of individuals who remain uninfected despite being
repeatedly exposed (85, 86). In fact, during the initial steps of
viral infection the virus needs to overcome the mucosal barrier
and to find proper target cells such as DCs, macrophages, acti-
vated CD4 T cells, to rapidly replicate and spread (87, 88). The
presence of intraepithelial DCs, capable of sampling the “outside”
and to rapidly bring and transfer the virus to neighbor CD4 T
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cells and activate them seems to be pivotal to infection estab-
lishment (87, 88). Accordingly, inflammation, immune activation
and mucosal lesions (mostly due to other sexually transmitted
infection, STI) enormously enhance sexual transmission (89, 90).
From this first focus of infected cells and through discrete rounds
of cryptic infection, virus establishes itself and initiates a pro-
ductive infection. Strikingly, evidence of ongoing residual virus
replication or reactivation have been reported even during sup-
pressive HAART, which somewhat recapitulate and mimic the
difficulties HIV encounters in the primary infection (91) Thus,
understanding and blocking the mechanism(s) of virus trans-
mission in primary as well as in chronic infection, in individuals
either asymptomatic and naïve to drug or on HAART, will conceiv-
ably lead, respectively, to protection from infection and to virus
eradication.
Thus, a “pathogenic-driven” strategy targeting a key virulence
factor might be effective in both the preventative (healthy people)
and the therapeutic approach (either in subjects naïve to drugs
or on cART), by acting with the same mechanisms, in prevent-
ing/controlling HIV infection/progression to disease. The out-
standing control and apparent eradication of infection conferred
by CTL responses elicited upon preventative immunization with
a CMV-vectored vaccine in a macaque model (58–60) is perhaps
one of the best examples of a successful prevention obtained with a
strategy aimed at inducing cellular responses (i.e., effector memory
CTL) known to be associated to non-sterilizing immunity. There-
fore, the distinction between preventative and therapeutic vaccine
concepts and strategies should not necessarily be considered in
terms of the development of different approaches, but rather in
terms of targeting distinct populations (i.e., uninfected individuals
vs. HIV-infected subjects) (Table 2). In considering this, it should
be noted that the conduction of therapeutic trials may prove very
useful and cost–effective in providing a first proof-of-concept of
efficacy of a vaccine design and better define specific end-points
and laboratory biomarkers to be assessed, before advancing to the
very expensive and time-consuming preventative trials (Table 2).
To these goals, novel immunological and virological biomark-
ers (in addition to viral load and CD4 T cell counts) should be
taken into consideration in trial design in order to assess the
achievement of efficacy end-points (i.e., assessment of functional
T and B cell subsets, cellular and biochemical immune activation
biomarkers, proviral DNA in reservoirs, cell-to-cell virus trans-
mission, and virus neutralization). This approach imposes new
challenges to the scientific community, vaccine developers and
regulatory bodies, which require new paradigms and a new “way
ahead.”
CONCLUSION
New paradigms must be applied to develop efficacious preven-
tative/therapeutic intervention strategies against HIV. These new
concepts may also serve to combat epidemics by other agents.
“Pathogenesis-driven” approaches should be considered with an
open-minded attitude and should constitute the basis for a ratio-
nale vaccine design, taking also into account that structures do not
always translate in immunogenicity and immunogenicity does not
always translate in efficacy. The disappointing results from efficacy
trials together with difficulties in translating preclinical studies to
clinical trials, including, but not limited to, the uncertain predic-
tivity of the results obtained in non-human primate models, also
indicate that vaccine candidates should first be tested in infected
individuals. This will provide a solid proof-of-concept to advance
to the very expensive and time-consuming preventative trials. Fur-
ther, new vaccine concepts and clinical trial designs should be
considered and supported with proper funding. This also requires
new methods for evaluation of projects where innovation is a key
indicator. In fact, new vaccine design may require different end-
points and biomarkers of efficacy as well as new testing for safety.
Thus, regulatory bodies must be involved at an early stage of devel-
opment and should be available to discuss the proper planning and
conduction of innovative approaches.
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